药物性肝衰竭研究进展

摘要/Abstract

摘要： 药物性肝衰竭(DILF)比例高,损伤机制多样,多数固有型和部分特异质型DILF可能与线粒体功能障碍、氧化应激、胆汁酸稳态改变有关,特异质性DILF是患者自身适应性免疫攻击的结果。DILF预后较差,是死亡和肝移植的重要原因,目前较多研究致力于重症化的早期预测和预后判断,产生了不同预测模型和生物学标志。

周霞, 姚红宇, 刘鸿凌. 药物性肝衰竭研究进展[J]. 肝脏, 2023, 28(3): 364-365.

[1] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 中华传染病杂志, 2019, 37(1):1-9.
[2] Hayashi PH, Rockey D, Fontana RJ, et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology, 2017, 66(4): 1275-1285
[3] Girish C, Sanjay S. Role of immune dysfunction in drug induced liver injury. World J Hepatol, 2021,13(11):1677-1687.
[4] Zhang IW, Curto A, López-Vicario C, et al. Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on -chronic liver failure. J Hepatol, 2022, 76(1): 93-106.
[5] Jee A, Sernoskie SC, Uetrecht J. Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges. Int J Mol Sci, 2021, 22(6):2954
[6] Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int, 2016, 36(2):158-165.
[7] Habib S, Shaikh OS . Drug-induced acute liver failure. Clinics in Liver Disease, 2017, 21(1):151-162.
[8] Chayanupatkul M, Schiano TD . Acute liver failure secondary to drug-induced liver injury. Clinics in Liver Disease, 2020, 24(1):75-87.
[9] Reuben A, Koch DG, Lee WM, Acute liver failure study group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology, 2010, 52(6):2065-2076.
[10] Watkins PB. How to diagnose and exclude drug-induced liver injury. Dig Dis, 2015, 33(4):472-476.
[11] Hoofnagle JH, Serrano J, Knoben JE, et al. LiverTox: A website on drug-induced liver injury. Hepatology, 2013, 57.
[12] Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology, 2015, 148(7):1340-52.e1347.
[13] Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int, 2015, 35(7):1801-1808
[14] Chalasani NP, Maddur H, Russo MW, et al. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2021, 00:1-21.
[15] Hayashi PH, Rockey DC, Fontana RJ, et al. Death and liver transplantation within two years of onset of drug-induced liver injury. Hepatology, 2017, 66(4): 1275-1285.
[16] Devarbhavi H, Patil M, Reddy VV, et al. Drug-induced acute liver failure in children and adults: results of a single-centre study of 128 patients. Liver Int, 2018, 38(7):1322-1329.
[17] Jeong R, Lee YS, Sohn C, et al. Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury . Scand J Gastroenterol, 2015, 50(4):439-446.
[18] Rathi C, Pipaliya N, Patel R, et al. Drug induced liver injury at a tertiary hospital in India: etiology, clinical features and predictors of mortality. Ann Hepatol, 2017, 16(3): 442-450.
[19] Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology, 2014,147(1):109-118.
[20] Bonkovsky HL, Barnhart HX, Foureau DM, et al. Cytokine profiles in acute liver injury-results from the US drug-induced liver Injury network (DILIN) and the acute liver failure study group. Plos One, 2018, 13(10):e0206389.
[21] Lo Re V, Haynes K, Forde KA, et al. Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy's law and a new prognostic model.Clin Gastroenterol Hepatol, 2015, 13(13):2360-2368.
[22] Roth SE, Avigan MI, Bourdet D, et al. Next-generation DILI biomarkers: prioritization of biomarkers for qualification and best practices for biospecimen collection in drug development. Clin Pharmacol Ther, 2020,107(2): 333-346.
[23] Llewellyn HP, Vaidya VS, Wang Z, et al. Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans . Toxicological Sciences, 2021,181(1):23-34.
[24] Russo MW, Steuerwald N, Norton HJ, et al. Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int, 2017, 37(5): 757-764.
[25] Arai M, Yokosuka O, Kanda T, et al. Serum osteopontin levels in patients with acute liver dysfunction. Scand. J. Gastroenterol, 2006, 41(1), 102-110.
[26] Church RJ, Kullak-Ublick GA, Aubrecht, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology, 2019, 69, 760-773.
[27] Bakshi S, Kaur M, Saini N, et al. Altered expressions of circulating microRNAs 122 and 192 during antitubercular drug induced liver injury indicating their role as potential biomarkers. Hum Exp Toxicol, 2021, 40(9):1474-1484.

药物性肝衰竭研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱云, 邹正升. 糖皮质激素在药物性肝损伤应用中的争鸣[J]. 肝脏, 2023, 28(3): 273-274.
[2]	胡伯斌, 王荣明, 梁蘅恺, 韦璐, 黎清梅, 苏土梅, 殷倩冰, 江建宁. ESPL1基因在肝细胞癌组织中的表达及其在预后评估中的作用[J]. 肝脏, 2023, 28(3): 285-289.
[3]	李芃芃, 董其刚, 许军. 慢加急性肝衰竭患者急性肾损伤的特点及其对预后的影响[J]. 肝脏, 2023, 28(3): 330-333.
[4]	许海玲, 章颖, 俞冲, 王忠成, 陈琳. 还原型谷胱甘肽联合PE+DPMAS治疗慢加急性肝衰竭的效果及预后评分模型的建立[J]. 肝脏, 2023, 28(3): 334-339.
[5]	陈可, 葛利丽. 药物性肝损伤和自身免疫性肝炎自身抗体以及血清免疫学特征分析[J]. 肝脏, 2023, 28(3): 340-342.
[6]	葛文俊, 刘军, 任俊. 122例急、慢性药物性肝损伤患者临床观察[J]. 肝脏, 2023, 28(3): 343-345.
[7]	尹僖, 叶玉伟, 王军, 张宏玲, 郑亚, 周永宁. 外周血炎症指标对慢加急性肝衰竭预后的研究[J]. 肝脏, 2023, 28(3): 377-380.
[8]	徐天娇, 田华, 游绍莉, 朱冰, 吕飒. 自身免疫性肝炎慢加急性肝衰竭的临床特征及预后分析[J]. 肝脏, 2023, 28(2): 157-161.
[9]	金建国, 华晴. 76例儿童急性肝衰竭病因及临床转归分析[J]. 肝脏, 2023, 28(2): 162-164.
[10]	许姗姗, 宋静静, 仇丽霞, 张晶. 血清总胆汁酸对伴胆汁淤积的药物性肝损伤的诊断价值[J]. 肝脏, 2023, 28(2): 218-221.
[11]	朱哿瑞, 马园园, 王帆, 黄恺, 彭渊, 陈高峰, 刘成海, 陶艳艳. 黄芪提取物调节TRPM2表达的抗急性药物性肝损伤作用研究[J]. 肝脏, 2023, 28(2): 222-228.
[12]	于鹏, 段绍斌. 术前MELD评分对肝包虫病患者手术后并发症和远期预后的评估价值[J]. 肝脏, 2023, 28(2): 229-232.
[13]	陈倩, 张清奇, 龚作炯. AMPK信号通路和NLRP3炎症小体在肝衰竭中的研究进展[J]. 肝脏, 2023, 28(2): 244-246.
[14]	赖曼, 王苏丹, 沈琳, 刘海霞. 以肝衰竭为首要表现的恶性血液系统疾病——附7例报道[J]. 肝脏, 2023, 28(1): 33-36.
[15]	翟庆慧, 刘婉姝, 田华, 李东泽, 辛绍杰. 肝硬化及并发症对慢加急性肝衰竭预后的影响[J]. 肝脏, 2023, 28(1): 37-40.